Share
News

Another COVID Vaccine Gets Encouraging Test Results as Fight Against Virus Gathers Strength

Share

New results on tests of a possible COVID-19 vaccine from Oxford University and AstraZeneca suggest it is safe and about 70 percent effective.

The vaccine seems likely to be approved, despite some confusion in the results and lower levels of protection than what some other vaccine candidates have shown.

“What we can see looks reasonable, but it’s a bit more complicated than what we’ve seen so far,” said Dr. Buddy Creech, a Vanderbilt University researcher helping to test two other vaccines.

“If this had been the first report out, the field would have still been excited to have a vaccine.”

The medical journal Lancet on Tuesday published partial results from tests of the vaccine in the United Kingdom, Brazil and South Africa — safety results on 23,745 participants and protection levels on 11,636.

Trending:
Fans Furious as Disney's 'Star Wars' Officially Jumps the Shark with Lesbian Witches Conceiving Babies in New Show

They’re hard to interpret because a mistake led some participants to get a half dose followed by a full one rather than two full doses as intended.

Researchers claim the vaccine protected against COVID-19 in 62 percent of those given two full doses and in 90 percent of those initially given the half dose.

However, independent experts have said the second group was too small — 2,741 people — to judge the possible value of that approach and that more testing is needed.

The half-dose group also didn’t include anyone over 55, and among others in the study, only about 12 percent were in that age group. Older people were enrolled later, so there hasn’t been enough time to see whether they develop infections at a lower rate than those not given the vaccine.

Are you encouraged by the results of this study?

It’s unclear if the results will be enough to lead regulators to approve its use right away.

“We have no safety concerns about the vaccine,” with no hospitalizations or severe disease among those who received it, and results from all study locations consistently showing benefit, according to one study leader, Oxford’s Andrew Pollard.

“The only way we get the pandemic behind us is if we get doses of vaccine out there,” he said.

AstraZeneca’s Mene Pangalos called the results “very compelling” and said they “clearly show we have an effective vaccine” that meets criteria for approval around the world.

“I really believe this vaccine will have a big impact on the pandemic,” he said.

Related:
Watch: Furious Democrats Ask Capitol Police to Kick Woman Out of Fauci Hearing - 'Take Your Starbucks with You!'

In the study, 10 people were hospitalized for COVID-19, none of whom received the vaccine. Two were considered severe cases, and one person died.

One person given the vaccine developed a neurological problem and has recovered.

The results come the same day that Britain started distributing another vaccine, from Pfizer and Germany’s BioNTech.

That vaccine and another developed by U.S. government scientists and made by Moderna seem about 95 percent effective in results announced so far. They work differently than AstraZeneca’s, which was developed by Oxford.

“Personally I’d be happy with any of these in my arm,” Pollard said.

Hopes are high for the AstraZeneca vaccine because it can be shipped and stored at normal refrigerator temperatures, unlike the others, which require freezing at around minus 94 degrees Fahrenheit.

That’s “very impractical” in developing countries, according to Dr. Gillies O’Bryan-Tear of Britain’s Faculty of Pharmaceutical Medicine.

In June, AstraZeneca said it could produce about 2 billion doses of the vaccine every year, with about half of those contracted to India’s Serum Institute for use in the developing world.

AstraZeneca has also signed licensing deals for the vaccine to be produced in countries including Brazil, South Africa and China.

COVAX, the global initiative led by the World Health Organization, has signed an agreement to obtain about 700 million doses of the AstraZeneca vaccine.


[jwplayer z0uIlRHg]

The Western Journal has reviewed this Associated Press story and may have altered it prior to publication to ensure that it meets our editorial standards.

Truth and Accuracy

Submit a Correction →



We are committed to truth and accuracy in all of our journalism. Read our editorial standards.

Tags:
, , , , , ,
Share
The Associated Press is an independent, not-for-profit news cooperative headquartered in New York City. Their teams in over 100 countries tell the world’s stories, from breaking news to investigative reporting. They provide content and services to help engage audiences worldwide, working with companies of all types, from broadcasters to brands. Photo credit: @AP on Twitter
The Associated Press was the first private sector organization in the U.S. to operate on a national scale. Over the past 170 years, they have been first to inform the world of many of history's most important moments, from the assassination of Abraham Lincoln and the bombing of Pearl Harbor to the fall of the Shah of Iran and the death of Pope John Paul.

Today, they operate in 263 locations in more than 100 countries relaying breaking news, covering war and conflict and producing enterprise reports that tell the world's stories.
Location
New York City




Conversation